Protagonist Therapeutics, Inc.PTGXNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P51
Within normal range
vs 2Y Ago
-0.1x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -8.47% |
| Q3 2025 | -10.42% |
| Q2 2025 | -117.72% |
| Q1 2025 | -115.23% |
| Q4 2024 | 405.84% |
| Q3 2024 | -6.86% |
| Q2 2024 | -118.80% |
| Q1 2024 | 795.09% |
| Q4 2023 | 160.14% |
| Q3 2023 | 9.51% |
| Q2 2023 | -17.58% |
| Q1 2023 | 1.36% |
| Q4 2022 | -13.04% |
| Q3 2022 | 22.05% |
| Q2 2022 | -96.31% |
| Q1 2022 | 44.32% |
| Q4 2021 | -11.76% |
| Q3 2021 | -9.86% |
| Q2 2021 | -28.56% |
| Q1 2021 | -27.57% |
| Q4 2020 | -142.28% |
| Q3 2020 | 57.34% |
| Q2 2020 | 7.51% |
| Q1 2020 | -13.86% |
| Q4 2019 | -0.77% |
| Q3 2019 | 45.34% |
| Q2 2019 | -114.41% |
| Q1 2019 | 4.96% |
| Q4 2018 | -64.15% |
| Q3 2018 | -1.62% |
| Q2 2018 | -12.27% |
| Q1 2018 | -134.24% |
| Q4 2017 | 29.46% |
| Q3 2017 | 67.09% |
| Q2 2017 | -6.01% |
| Q1 2017 | -25.23% |
| Q4 2016 | -59.67% |
| Q3 2016 | -0.66% |
| Q2 2016 | -0.72% |
| Q1 2016 | -40.77% |